相关实验视频
Updated: Sep 13, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.0K
[抗血小板因素4 (PF4) 相关疾病:从药物不良反应到血栓性疾病]
Linda Schönborn1, Andreas Greinacher1, Thomas Thiele2
1Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, 17487, Greifswald, Deutschland.
Innere Medizin (Heidelberg, Germany)
|July 25, 2025
概括
对血小板衍生因子4 (anti-PF4) 的抗体会导致像HIT和VITT这样的免疫血栓形成. 诊断包括检测抗PF4抗体和血小板激活,治疗重点是抗凝血,IVIG或针对潜在疾病.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 血栓形成研究研究
背景情况:
- 对血小板衍生因子4 (anti-PF4) 的抗体与严重的血栓事件有关.
- 这些抗体是肝素诱导的血小板缺血症 (HIT),疫苗或病毒诱导的免疫血小板缺血症和血栓症 (VITT),以及具有血栓性意义的慢性单克隆性胃病变 (MGTS) 的核心.
研究的目的:
- 审查抗PF4相关免疫血栓性疾病的分类,诊断和治疗.
- 巩固临床医生和研究人员对这些疾病的当前理解.
主要方法:
- 对抗PF4相关的血栓性疾病的文献综述.
- 诊断标准的总结,包括抗体检测和功能测试.
- 目前和新兴的治疗策略的概述.
主要成果:
- 抗PF4抗体激活血小板,导致动脉和静脉血栓形成,通常伴有血小板减少.
- 急性呈现 (HIT,VITT) 发生在触发后 (肝素,病毒感染) 在特定的时间框架内.
- 诊断依赖于血清学和功能测试;治疗包括抗凝剂,IVIG,并解决诸如单克隆性乳腺病变等潜在疾病.
结论:
- 抗PF4相关的血栓形成代表了一系列免疫媒介疾病,需要准确的诊断.
- 有效的管理策略包括迅速的抗凝血,免疫调节和针对慢性形式的向治疗.
- 对新型治疗方法的进一步研究,如布鲁顿的氨酸激酶抑制剂,显示了控制血小板激活的前景.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
911
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
911
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
646
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
646
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Formation of the Platelet Plug
7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Factors Affecting Protein-Drug Binding: Drug Interactions
280
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
280
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K

